Integrating Bispecific Antibodies Into VA Oncology Care: A VISN 20 Multidisciplinary Protocol and Education ModelAugust 13, 2026Multiple MyelomaOncology
Agent Orange Exposure Increases Lymphoma Risk in Million Veteran Program CohortNovember 11, 2025OncologyLymphoma & Plasma Cell DisordersMultiple Myeloma
A Case Report on Bortezomib-Induced Hypotension: Rare Adverse Effect in Proteasome Inhibitor TherapySeptember 3, 2025OncologyMultiple MyelomaHematology
Case Presentation: First Ever VA "Bloodless" Autologous Stem Cell Transplant Was a SuccessAugust 28, 2025OncologyHematologyMultiple Myeloma
Service Connection Expanded to Additional CancersJanuary 31, 2025Prostate CancerLeukemia, Myelodysplasia, TransplantationMultiple MyelomaGenitourinary Cancer
New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?December 12, 2024Mixed TopicsBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell Disorders
Inside the Patient-Oncologist Bond: Why It’s Often So StrongDecember 2, 2024Breast CancerMixed TopicsGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell Disorders
Outpatient CAR T: Safe, Effective, AccessibleNovember 4, 2024Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaMixed TopicsOncologyHematology
Cancer Risk: Are Pesticides the New Smoking?September 20, 2024OncologyBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell Disorders
RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple MyelomaSeptember 10, 2024OncologyMultiple Myeloma
